Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Zealand Pharma A/S

22Z
Current price
111.8 EUR +6.81 EUR (+6.48%)
Last closed 107.1 EUR
Company
ISIN DK0060257814
Sector Healthcare
Industry Biotechnology
Exchange Frankfurt Exchange
Capitalization 7 924 005 543 EUR
Yield for 12 month +180.34 %
1Y
3Y
5Y
10Y
15Y
22Z
21.11.2021 - 28.11.2021

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark. Address: Sydmarken 11, Søborg, Denmark, 2860

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

204.75 EUR

P/E ratio

Dividend Yield

Current Year

+45 717 910 EUR

Last Year

+13 868 696 EUR

Current Quarter

+4 552 078 EUR

Last Quarter

+2 012 432 EUR

Current Year

+43 160 658 EUR

Last Year

+13 868 696 EUR

Current Quarter

+3 286 523 EUR

Last Quarter

+1 399 327 EUR

Key Figures 22Z

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -709 360 366 EUR
Operating Margin TTM -784.27 %
PE Ratio
Return On Assets TTM -7.38 %
PEG Ratio
Return On Equity TTM -12.8 %
Wall Street Target Price 204.75 EUR
Revenue TTM 365 988 399 EUR
Book Value 131.77 EUR
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 228 %
Dividend Yield
Gross Profit TTM 103 425 450 EUR
Earnings per share -1.52 EUR
Diluted Eps TTM -1.52 EUR
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -193.49 %

Dividend Analytics 22Z

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 22Z

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 22Z

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 139.0266
Price Sales TTM 21.651
Enterprise Value EBITDA -7.1603
Price Book MRQ 6.3085

Financials 22Z

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 22Z

For 52 weeks

36.7 EUR 129.7 EUR
50 Day MA 112.64 EUR
Shares Short Prior Month
200 Day MA 96.58 EUR
Short Ratio
Shares Short
Short Percent